Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MC4R | P32245 | 3/20 | 0.75 |
| ▸ | MC5R | P33032 | 2/20 | 0.75 |
| ▸ | MC3R | P41968 | 2/20 | 0.75 |
| ▸ | MC1R | Q01726 | 2/20 | 0.75 |
| ▸ | C5AR1 | P21730 | 2/20 | 0.71 |
| ▸ | CTSL | P07711 | 3/20 | 0.68 |
| ▸ | CTSS | P25774 | 3/20 | 0.68 |
| ▸ | CTSK | P43235 | 3/20 | 0.68 |
| ▸ | CTSH | P09668 | 1/20 | 0.68 |
| ▸ | GLP1R | P43220 | 4/20 | 0.64 |
| ▸ | GCGR | P47871 | 3/20 | 0.63 |
| ▸ | NMBR | P28336 | 1/20 | 0.62 |
| ▸ | GRPR | P30550 | 1/20 | 0.62 |
| ▸ | IL23R | Q5VWK5 | 1/20 | 0.62 |
| ▸ | CXCR4 | P61073 | 4/20 | 0.62 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Codactide SCHEMBL29409825 | 0.97 | MC4R (0.74) | MC4RMC5RMC3RMC1RC5AR1 | |
| Alsactide SCHEMBL29406207 | 0.96 | C5AR1 (0.74) | MC4RMC5RMC3RMC1RC5AR1 | |
| SCHEMBL18388638 | 0.95 | C5AR1 (0.74) | MC4RMC5RMC3RMC1RC5AR1 | |
| SCHEMBL29358645 | 0.95 | MC4R (0.82) | MC4RMC5RMC3RMC1RC5AR1 | |
| Intermedine SCHEMBL22076809 | 0.95 | MC4R (0.82) | MC4RMC5RMC3RMC1RC5AR1 | |
| Intermedine SCHEMBL20548027 | 0.95 | MC4R (0.82) | MC4RMC5RMC3RMC1RC5AR1 | |
| SCHEMBL29973172 | 0.94 | C5AR1 (0.77) | MC4RMC5RMC3RMC1RC5AR1 | |
| SCHEMBL29430238 | 0.94 | MC4R (0.78) | MC4RMC5RMC3RMC1RC5AR1 | |
| SCHEMBL29533733 | 0.94 | MC4R (0.78) | MC4RMC5RMC3RMC1RC5AR1 | |
| SCHEMBL29534172 | 0.94 | MC4R (0.78) | MC4RMC5RMC3RMC1RC5AR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240074995-A1 | METHODS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH AN ABNORMAL INFLAMMATORY RESPONSES | FIRST WAVE BIO, INC. | 2024-03-07 | — | — | US | disclosed |
| US-11793777-B2 | Methods and compositions for treating conditions associated with an abnormal inflammatory response | FIRST WAVE BIO, INC. (US) | 2023-10-24 | — | — | US | disclosed |
| US-11744812-B2 | Methods of treatment | FIRST WAVE BIO, INC. (US) | 2023-09-05 | — | — | US | disclosed |
| US-20230201143-A1 | METHODS OF TREATMENT | FIRST WAVE BIO, INC. | 2023-06-29 | — | — | US | disclosed |
| US-20230102999-A1 | DEUTERATED NICLOSAMIDE | FIRST WAVE BIO, INC. | 2023-03-30 | — | — | US | disclosed |
| US-11564896-B2 | Methods of treatment | FIRST WAVE BIO, INC. (US) | 2023-01-31 | — | — | US | disclosed |
| EP-4045480-A1 | PHARMACEUTICAL FORMULATIONS | First Wave Bio, Inc. (US) | 2022-08-24 | — | — | EP | disclosed |
| US-20220105057-A1 | METHODS OF TREATMENT | FIRST WAVE BIO, INC. | 2022-04-07 | — | — | US | disclosed |
| US-20220079897-A1 | METHODS OF TREATMENT | FIRST WAVE BIO, INC. | 2022-03-17 | — | — | US | disclosed |
| US-20220047505-A1 | Controlled Absorption Water-Soluble Pharmaceutically Active Organic Compound Formulation for Once-Daily Administration | STI PHARMA, LLC (US) | 2022-02-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240074995-A1 | METHODS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH AN ABNORMAL INFLAMMATORY RESPONSES | FH, CS, ECHS1 | MC4R 2240/4885MC5R 2262/4885MC3R 2710/4885 |
| US-20220079897-A1 | METHODS OF TREATMENT | ACE2, ACE, SI | MC4R 2077/4885MC5R 2679/4885MC3R 2630/4885 |
| US-11744812-B2 | Methods of treatment | ACE2, ACE, SI | MC4R 2077/4885MC5R 2679/4885MC3R 2630/4885 |
| US-20230201143-A1 | METHODS OF TREATMENT | ACE2, ACE, SI | MC4R 1888/4885MC5R 2483/4885MC3R 2704/4885 |
| US-11564896-B2 | Methods of treatment | ACE2, ACE, SI | MC4R 1888/4885MC5R 2483/4885MC3R 2704/4885 |
| US-20220105057-A1 | METHODS OF TREATMENT | ACE2, ACE, SI | MC4R 1888/4885MC5R 2483/4885MC3R 2704/4885 |
| US-20230102999-A1 | DEUTERATED NICLOSAMIDE | FH, IDH2, ECHS1 | MC4R 2181/4885MC5R 2290/4885MC3R 2346/4885 |
| US-11793777-B2 | Methods and compositions for treating conditions associated with an abnormal inflammatory response | FH, CS, ECHS1 | MC4R 2178/4885MC5R 2175/4885MC3R 2636/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.